EA202091007A1 - Способ снижения времени восстановления высушенных распылением белковых составов - Google Patents

Способ снижения времени восстановления высушенных распылением белковых составов

Info

Publication number
EA202091007A1
EA202091007A1 EA202091007A EA202091007A EA202091007A1 EA 202091007 A1 EA202091007 A1 EA 202091007A1 EA 202091007 A EA202091007 A EA 202091007A EA 202091007 A EA202091007 A EA 202091007A EA 202091007 A1 EA202091007 A1 EA 202091007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spray
dried protein
protein compositions
restoration time
reducing
Prior art date
Application number
EA202091007A
Other languages
English (en)
Inventor
Мартен Бейтенс
Жан Иво Массан
Original Assignee
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Срл filed Critical Юсб Биофарма Срл
Publication of EA202091007A1 publication Critical patent/EA202091007A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к применению сочетания сахара и одной или более аминокислот для снижения времени восстановления высушенного распылением белкового состава.
EA202091007A 2017-11-15 2018-11-13 Способ снижения времени восстановления высушенных распылением белковых составов EA202091007A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1718888.9A GB201718888D0 (en) 2017-11-15 2017-11-15 Method
PCT/EP2018/081058 WO2019096776A1 (en) 2017-11-15 2018-11-13 Method for reducing the reconstitution time of spray-dried protein formulations

Publications (1)

Publication Number Publication Date
EA202091007A1 true EA202091007A1 (ru) 2020-08-14

Family

ID=60788489

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091007A EA202091007A1 (ru) 2017-11-15 2018-11-13 Способ снижения времени восстановления высушенных распылением белковых составов

Country Status (9)

Country Link
US (1) US20200390705A1 (ru)
EP (1) EP3709977A1 (ru)
JP (1) JP2021502990A (ru)
CN (1) CN111417385A (ru)
BR (1) BR112020009096A2 (ru)
CA (1) CA3081645A1 (ru)
EA (1) EA202091007A1 (ru)
GB (1) GB201718888D0 (ru)
WO (1) WO2019096776A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
WO2022271544A1 (en) * 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
TW202332471A (zh) * 2021-12-01 2023-08-16 比利時商Ｕｃｂ生物製藥公司 調配物
WO2023242347A1 (en) 2022-06-15 2023-12-21 Sanofi Highly concentrated antibody compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1275331A (en) * 1970-03-06 1972-05-24 Cerebos Foods Ltd Instantised products
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
EP1755677A4 (en) * 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
EP4059492B1 (en) * 2015-12-16 2024-04-17 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
EP3434283A4 (en) * 2016-03-25 2019-11-13 Astellas Pharma Inc. MEDICINAL COMPOSITION CONTAINING FAB 'FRAGMENT OF ANTI-NGF PEG HUMAN ANTIBODIES
CN105838610A (zh) * 2016-05-17 2016-08-10 吉林农业大学 一种益生菌直投式发酵剂喷雾干燥方法

Also Published As

Publication number Publication date
BR112020009096A2 (pt) 2020-10-20
CA3081645A1 (en) 2019-05-23
JP2021502990A (ja) 2021-02-04
CN111417385A (zh) 2020-07-14
EP3709977A1 (en) 2020-09-23
WO2019096776A1 (en) 2019-05-23
GB201718888D0 (en) 2017-12-27
US20200390705A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EP3936141A3 (en) Anti-senescence compounds and uses thereof
EA201990071A1 (ru) Композиция пептидной вакцины
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
IL286592A (en) Amino acid compounds for the treatment of liver disease
PH12018502714A1 (en) Nicotine particles and compositions
DK3658132T3 (da) Sammensætninger omfattende aminosyrer til anvendelse ved behandling af mitokondrielle dysfunktion-relaterede sygdomme
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
MX2020001885A (es) Formulaciones de daptomicina.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
DK3604304T3 (da) Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
DK3630977T3 (da) Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.